ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,997,391 | $1,012,377 | $767,755 | $196,806 |
| - Cash | $103,147 | $51,352 | $86,522 | $51,089 |
| + Debt | $82,116 | $141,418 | $154,443 | $102,920 |
| Enterprise Value | $3,976,360 | $1,102,443 | $835,676 | $248,636 |
| Revenue | $426,454 | $258,215 | $154,080 | $80,943 |
| % Growth | 65.2% | 67.6% | 90.4% | – |
| Gross Profit | $219,553 | $88,942 | $35,265 | $1,173 |
| % Margin | 51.5% | 34.4% | 22.9% | 1.4% |
| EBITDA | $147,689 | $5,120 | -$39,512 | -$53,095 |
| % Margin | 34.6% | 2% | -25.6% | -65.6% |
| Net Income | $197,673 | -$28,239 | -$65,904 | -$71,648 |
| % Margin | 46.4% | -10.9% | -42.8% | -88.5% |
| EPS Diluted | 0.81 | -0.13 | -0.43 | -0.61 |
| % Growth | 723.1% | 69.8% | 29.5% | – |
| Operating Cash Flow | $118,672 | $8,800 | -$59,508 | -$112,369 |
| Capital Expenditures | -$8,575 | -$4,981 | -$13,911 | -$13,511 |
| Free Cash Flow | $110,097 | $3,819 | -$73,419 | -$125,880 |